Form 4: VolitionRx Executive Acquires Shares Following RSU Vesting

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx, reports acquisition of shares due to vesting of restricted stock units (RSUs).

Summary

• On August 15, 2024, Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRx Ltd, reported a transaction involving the acquisition of 13,750 shares of common stock.
• These shares were obtained through the vesting of restricted stock units (RSUs) previously awarded under the company's 2015 Stock Incentive Plan.
• The vesting was contingent upon achieving certain corporate performance goals by December 31, 2023, and June 30, 2024, as well as time-based vesting.
• Certain performance goals were met, leading to the vesting of these 13,750 RSUs.
• The RSUs are subject to a 3-year time-based vesting schedule, with installments vesting on September 28, 2024, 2025, and 2026.
• An additional 23,375 RSUs had previously vested and remain subject to time-based vesting.
• 17,875 RSUs did not vest and were cancelled on August 15, 2024.
• Following the reported transaction, Micallef directly owns 312,974 shares of common stock.
• Micallef also indirectly owns 55,000 shares through his spouse and 38,113 shares through Borlaug Limited, where he is a controlling director.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily reporting a routine transaction. The vesting of some RSUs is a mild positive, while the cancellation of others is a mild negative.

Positives

• The vesting of RSUs indicates that certain corporate performance goals were achieved, which could be seen as a positive sign for the company's progress.

Negatives

• The cancellation of 17,875 RSUs suggests that some performance goals were not met, which could be a concern.

Risks

• The future vesting of RSUs is dependent on continued time-based vesting, which could be affected by changes in employment or other factors.

Future Outlook

Future vesting of RSUs is subject to continued time-based vesting on September 28, 2024, 2025 and 2026.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• RSUs are a common form of equity compensation used to incentivize executives and align their interests with company performance, similar to practices at companies like Exact Sciences and Guardant Health.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns management's interests with the company's performance.

Key Dates